IMMUNE CHECKPOINT INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER: T-cell-directed strategies represent currently a major advance in the treatment of advanced non-small-cell lung cancer, regarding their efficacy and tolerance. Nivolumab and pembrolizumab, two monoclonal antibodies targeting programmed cell death protein 1 (PD-1) have shown their efficacy in phase III studies. Several other drugs are developed and the benefit of association is being evaluated. In this article, we propose to summarize the clinical development of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0007-4551(16)30371-X | DOI Listing |
Publication Analysis
Top Keywords
lung cancer
12
immune checkpoint
8
checkpoint inhibitors
8
advanced non-small
8
non-small cell
8
cell lung
8
[not available]
4
available] immune
4
inhibitors advanced
4
cancer t-cell-directed
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!